LTRN Lantern Pharma Inc.

FDA Catalyst Company
6.11
+0.11  (+2%)
Previous Close 6
Open 6
52 Week Low 4.9977
52 Week High 16.5
Market Cap $66,177,086
Shares 10,830,947
Float 8,819,920
Enterprise Value $-62,306
Volume 11,244
Av. Daily Volume 23,387
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/11/2022
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/02/2021
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 10/07/2021

Latest News

  1. Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Company's management will be speaking at five investor and scientific conferences in May 2022.

    Dr. Kishor Bhatia, Lantern's Chief Scientific Officer, will be speaking at the 9th Drug Discovery Strategic Summit on May 9th, and presenting on the synthetic lethality potential of Lantern's drug candidates. Additionally, Panna Sharma, Lantern's Chief Executive Officer and President, will be speaking at four events in May, including the Strategic Investment Conference…

    View Full Article
    • RADR®, Lantern's proprietary A.I. and machine learning platform, has now surpassed 20 billion data points, enhancing its precision, insights, and capabilities for oncology drug discovery
    • Launch and enrollment of the HARMONIC™ clinical trial expected in Summer of 2022; the Phase 2 trial is for LP-300 in never-smokers with lung cancer
    • IND application for LP-184 targeted for submission with the FDA in Q3 2022; enabling a first in-human clinical trial for genomically defined solid tumors
    • Announced brain metastases as a new indication being pursued for LP-184 at the American Association of Cancer Research annual meeting
    • Advanced preclinical studies are underway in Australia, through Australian subsidiary, Lantern Pharma Australia Pty Ltd., to take advantage…
    View Full Article
View All Lantern Pharma Inc. News